Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.

Literature DB >> 6385429

The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.

G A Ellard.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Isoniazid

Year: 1984 PMID： 6385429 DOI： 10.1016/0041-3879(84)90079-5

Source DB: PubMed Journal: Tubercle ISSN： 0041-3879

Keyword Cloud
Cited

× No keyword cloud information.

17 in total

1. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors: Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal: Clin Infect Dis Date: 2012-03-30 Impact factor: 9.079

2. Acetylator status of kwashiorkor children in Ibadan (south-west Nigeria).

Authors: L H Jeyakumar; U A Arowoshegbe; O O Akinyinka; F O Akinbami; E A Bababunmi
Journal: Eur J Drug Metab Pharmacokinet Date: 1990 Jan-Mar Impact factor: 2.441

3. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

Authors: Maxwell T Chirehwa; Helen McIlleron; Lubbe Wiesner; Dissou Affolabi; Oumou Bah-Sow; Corinne Merle; Paolo Denti
Journal: J Antimicrob Chemother Date: 2019-01-01 Impact factor: 5.790

Review 4. Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors: J G Douglas; M J McLeod
Journal: Clin Pharmacokinet Date: 1999-08 Impact factor: 6.447

5. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.

Authors: Alma Tostmann; Charles M Mtabho; Hadija H Semvua; Jossy van den Boogaard; Gibson S Kibiki; Martin J Boeree; Rob E Aarnoutse
Journal: Antimicrob Agents Chemother Date: 2013-04-29 Impact factor: 5.191

6. Ameliorating role of caffeic acid phenethyl ester (CAPE) against isoniazid-induced oxidative damage in red blood cells.

Authors: Osman Gokalp; Efkan Uz; Ekrem Cicek; H Ramazan Yilmaz; Mehmet Kaya Ozer; Ayse Altunbas; Nurten Ozcelik
Journal: Mol Cell Biochem Date: 2006-09-09 Impact factor: 3.396

The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.

1. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

2. Acetylator status of kwashiorkor children in Ibadan (south-west Nigeria).

3. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

Review 4. Pharmacokinetic factors in the modern drug treatment of tuberculosis.

5. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.

6. Ameliorating role of caffeic acid phenethyl ester (CAPE) against isoniazid-induced oxidative damage in red blood cells.

Review 7. Nervous system effects of antituberculosis therapy.

8. Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012.

9. Isoniazid protects mice against endotoxin lethality without influencing tumor necrosis factor synthesis and release.

Review 10. Neurological manifestations and toxicities of the antituberculosis drugs. A review.